P2RY8 is detected as a mutational cancer driver in the Non-Hodgkin Lymphoma from PCAWG cohort
P2RY8 reports in Non-Hodgkin Lymphoma from PCAWG
Cohort details
| Non-Hodgkin Lymphoma from PCAWG |
|---|
| Non-Hodgkin Lymphoma NHL |
|
105
Samples
Driver genes 55 Mutations 1,340,919 |
|
Source
PCAWG
Reference doi:10.1101/162784 |
|
Type
Primary
Treated No Age Adult Platform WGS |
Gene details
| P2RY8 |
|---|
|
Gene ID
ENSG00000182162
Transcript ID ENST00000381297 Protein ID ENSP00000370697 |
|
Mutated samples
12
Mutated samples (%) 11.43 Mutations 15 |
| Known driver True |
Method signals
| Cohort | Methods | Samples | Samples (%) |
|---|
ClustL
HotMAPS
smRegions
Clustered Mutations
CBaSE dNdScv Recurrent Mutations
FML Functional Mutations
MutPanning Tri-nucleotide specific bias
combination Combination
CBaSE dNdScv Recurrent Mutations
FML Functional Mutations
MutPanning Tri-nucleotide specific bias
combination Combination
Observed mutations in tumors
The mutations needle plot shows the distribution of the observed
mutations along the protein sequence.
| Mutation (GRCh38) | Protein Position | Samples | Samples (%) | Consequence | Driver | Driver score |
|---|
The excess of mutations per consequence type measures the percentage of driver mutations.
More specifically, it quantifies the proportion of mutations among the ones that have been observed
that are not explained by the neutral mutation model.
The excess is obtained from the from the dNdScv estimates.